- $36.71bn
- $43.10bn
- $9.89bn
Biogen's Alzheimer’s drug fails to meet mid-stage trial goal
Brief: Topline Results From Phase 2 Celia Study Of Diranersen,First Study To Show Reduction In Tau Pathology And Cognitive Benefit In Patients With Early Alzheimer'S Disease
Roche gets second European approval for Alzheimer's test
U.S. STOCKS ON THE MOVE-Corning, BILL Holdings, Moderna
U.S. STOCKS ON THE MOVE-Corning, Moderna, News Corp
U.S. STOCKS ON THE MOVE-Coinbase, Microchip, Wendy's
U.S. STOCKS ON THE MOVE-Cloudflare, IREN, Monster Beverage
Biogen down after US FDA extends review of Alzheimer's drug
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
U.S. STOCKS ON THE MOVE-Biogen, Fair Isaac, General Dynamics
Biogen climbs after quarterly profit beat
Biogen cuts annual profit forecast on acquisition-related charges (updated)
Biogen Q1 revenue and adjusted EPS beat, lowers 2026 outlook
Brief: Biogen Q1 Adjusted EPS USD 3.57 Vs. IBES Estimate USD 2.77
Biogen cuts annual profit forecast on acquisition-related charges
Brief: Biogen Outlook FY Adjusted EPS $14.25 To $15.25 Vs IBES Estimate $15.04
U.S. RESEARCH ROUNDUP-CME Group, GE Vernova, Texas Instruments
U.S. STOCKS ON THE MOVE-Adobe, Biogen, Sable
U.S. STOCKS ON THE MOVE-Adobe, Agios, QXO